Novo Nordisk, Wegovy
EMA CHMP recommends label update to Novo Nordisk’s Wegovy
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended an update to Novo Nordisk’s Wegovy label.
Novo Nordisk's Wegovy Recommended For Label Update To Reflect Heart Failure Benefits
Novo Nordisk said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a
Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function
BAGSVAERD, Denmark I 19, 2024 I Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human
EU regulator backs use of Novo's Wegovy for obesity-related heart condition
The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with obesity, the Danish drugmaker said on Thursday. This marks the regulator's second backing for a use of Wegovy beyond weight loss and further strengthens Novo's case that the medicine has multiple health benefits.
What Expanded CVD Medicare Coverage May Mean for Novo Nordisk’s Wegovy
A recent study estimated that Wegovy’s label expansion beyond obesity could push Medicare spending to $145 billion annually, but analysts remain dubious of the estimate.
Novo Nordisk’s Wegovy Gets EU Backing to Treat Obesity-Related Heart Failure
Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure in obese patients.
Hims & Hers offers compounded Wegovy for $99 a month to select professions
U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular ...
STAT1d
Pharmalittle: We’re reading about a rare-disease drug bill, compounded Wegovy, and more
For patients on a 12-month plan, Hims offers a semaglutide injection for $199 a month. Ozempic and Wegovy carry high list prices of $935.77 and $1,349.02, respectively, for a month’s supply, ...
Everyday Health6d
Wegovy May Reduce the Risk of Death From COVID-19, Study Suggests
A new study found that people taking Wegovy during the pandemic were 33 percent less likely to die of COVID-19.
Wegovy, Ozempic may someday be available as monthly injection
A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of the ...
Experimental Weight Loss Drug Beat Ozempic and Wegovy in Early Trial
People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the ...
Medscape6d
Semaglutide Reduces MACE, Death in Participants With CVD, Overweight/Obesity, and Impaired Kidney Function
A SELECT trial subanalysis showed that semaglutide works as well in people with CVD, overweight/obesity, and impaired kidney ...
healthday on MSN10d
Wegovy, Ozempic May Someday Be Given as Once-Monthly Injection
A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of ...
MedPage Today1d
Is Wegovy Shrinking Bariatric Surgery, Too?
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Glucagon-like peptide 1 (GLP-1) receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, ...